🇺🇸 FDA
Patent

US 11401267

Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof

granted A61PA61P35/00A61P37/00

Quick answer

US patent 11401267 (Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof) held by NURIX THERAPEUTICS, INC. expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
NURIX THERAPEUTICS, INC.
Grant date
Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61P, A61P35/00, A61P37/00